The present invention relates uses of an S1 P receptor modulator such as 2-substituted 2- amino- propane-1,3-diol or 2-amino-propanol derivatives, e. g. a compound comprising a group of formula (X) for the treatment or prevention of neo-angiogenesis associated with a demyelinating disease, e.g. multiple sclerosis.